Academic Journal
Hand-dominant joint involvement pattern associates with favourable, and polyarthritis with unfavourable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trials.
| Τίτλος: | Hand-dominant joint involvement pattern associates with favourable, and polyarthritis with unfavourable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trials. |
|---|---|
| Συγγραφείς: | Nagafuchi Y; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: y.nagafuchi@lumc.nl., Maarseveen TD; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Lend K; Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Division of Rheumatology, Department of Medicine, Center for Molecular Medicine (CMM), Karolinska Institute, Stockholm, Sweden., Rudin A; Rheumatology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, Gothenburg, Sweden., Gudbjornsson B; Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Nordström D; Departments of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland; University of Helsinki, Helsinki, Finland., Haavardsholm EA; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Gröndal G; Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Lampa J; Division of Rheumatology, Department of Medicine, Center for Molecular Medicine (CMM), Karolinska Institute, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden., Petersen KH; Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Syddanmark, Denmark., Heiberg MS; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway., Hetland ML; Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Nurmohamed M; Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Amsterdam Rheumatology and Immunology Center, Reade Amsterdam, Noord-Holland, The Netherlands., Østergaard M; Department of Clinical Medicine, University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Denmark; Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., van Vollenhoven R; Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Rheumatology, Semmelweis University, Budapest, Hungary., Uhlig T; Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway; University of Oslo, Oslo, Norway., Sokka-Isler T; Department of Medicine and University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland., van den Akker EB; Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, The Netherlands; Pattern Recognition & Bioinformatics, Delft University of Technology, Delft, The Netherlands., Huizinga TWJ; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Bergstra SA; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands., Knevel R; Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands; Pattern Recognition & Bioinformatics, Delft University of Technology, Delft, The Netherlands; Newcastle University School of Clinical Medical Sciences, Newcastle upon Tyne, UK. |
| Πηγή: | Annals of the rheumatic diseases [Ann Rheum Dis] 2026 Jul; Vol. 85 (7), pp. 1218-1228. Date of Electronic Publication: 2026 Mar 08. |
| Τύπος έκδοσης: | Journal Article; Meta-Analysis |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: BMJ Country of Publication: United States NLM ID: 0372355 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-2060 (Electronic) Linking ISSN: 00034967 NLM ISO Abbreviation: Ann Rheum Dis Subsets: MEDLINE |
| Imprint Name(s): | Publication: London : BMJ Original Publication: London : H.K. Lewis |
| Ιατρικοί όροι (MeSH): | Arthritis, Rheumatoid*/drug therapy , Arthritis, Rheumatoid*/pathology , Arthritis, Rheumatoid*/physiopathology , Antirheumatic Agents*/therapeutic use , Hand Joints*/physiopathology , Hand Joints*/pathology , Biological Products*/therapeutic use , Arthritis*/drug therapy, Humans ; Female ; Treatment Outcome ; Male ; Middle Aged ; Severity of Illness Index ; Randomized Controlled Trials as Topic ; Treatment Effect Heterogeneity |
| Περίληψη: | Objectives: To investigate the association between joint involvement pattern (JIP) subgroups and treatment responses to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biological disease-modifying antirheumatic drugs (bDMARDs), and to compare the impact of JIP subgroups with other clinical parameters in treatment-naïve patients with early rheumatoid arthritis (RA). Methods: An individual patient data meta-analysis was conducted using 2 randomised controlled trials, NOrdic Rheumatic Diseases Strategy Trials And Registries (NORD-STAR) and Behandel-Strategieën (BeSt), including 1250 treatment-naïve patients with early RA. JIP subgroup assignment was based on 4 previously identified subgroups defined by baseline clinical characteristics, primarily joint involvement in the 66/68 joint scheme. Treatment outcomes were measured using the longitudinal Clinical Disease Activity Index (CDAI) and other disease activity indices through week 48. Associations of the JIP subgroups and other clinical predictors were evaluated using a mixed-model analysis. Results: Patients with a hand-dominant JIP (JIP-Hand) showed significantly better CDAI scores after treatment (Beta for CDAI = -1.4 [95% CI, -2.3 to -0.55]; p = .0016), whereas those with a polyarthritis pattern (JIP-Poly) exhibited worse outcomes (Beta = 0.95 [95% CI, 0.064-1.8]; p = .035). Female sex was also associated with worse CDAI scores (Beta = 1.2 [95% CI, 0.40-2.0]; p = .0031), whereas anticitrullinated protein antibodies did not show a significant association (Beta = 0.19 [95% CI, -0.69 to 1.1]; p = .67). When compared across groups, csDMARDs and combined bDMARDs were similarly effective in the respective JIP subgroups (interaction p > .10). Conclusions: In early RA, csDMARD and bDMARD treatments resulted in the greatest improvement in disease activity in JIP-Hand and the least improvement in JIP-Poly. (Copyright © 2026 The Author(s). Published by Elsevier B.V. All rights reserved.) |
| Competing Interests: | Competing interests YN reports research grants from BMS; speaker fees from BMS. YN belonged to the Social Cooperation Program, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, the University of Tokyo, supported by Chugai Pharmaceutical. DN reports a research grant from MSD and consultation fees from Lilly, MSD, Novartis, and UCB. MH has received grants or contracts from the following (if not indicated above): AbbVie, Alfasigma, BMS, Eli Lilly, MSD, UCB, Novartis, Sandoz, Pfizer, and Nordforsk (all research grants paid to the institution); payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from Pfizer, Medaq, Sandoz, and UCB (all paid to the institution); payment from Novartis (personal and institutional); and participation on a Data Safety Monitoring Board or Advisory Board for AbbVie (paid to the institution). MH cochairs EuroSpA, which generates real-world evidence on the treatment of psoriatic arthritis and axial spondylarthritis based on secondary data and is partly funded by Novartis, UCB, and AbbVie. MØ has received research grants from AbbVie, Amgen, BMS, Merck, Celgene, Eli Lilly, Novartis, and UCB; speaker fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, MEDAC, Merck, Novartis, Pfizer, Sandoz, and UCB; and consultancy fees from AbbVie, BMS, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, and UCB. RvV reports research support (institutional grants) from AstraZeneca, BMS, Cabaletta, Novartis, and RemeGen; support for educational programmes (institutional grants) from Alfasigma, AstraZeneca, Galapagos, MSD, Novartis, Pfizer, Roche, Sanofi, and UCB; consultancy and/or speaker for AbbVie, AstraZeneca, Biogen, BMS, Cabaletta, Galapagos, GSK, Janssen, Kyowakirin, Pfizer, RemeGen, Sanofi, UCB, and Vorbio. TU reports honoraria from Lilly, Pfizer, and UCB. TS-I reports honoraria from AbbVie, Lipum, Pfizer, Nordic Medicine, and UCB; research grant support from Amgen and Nordic Pharma. SAB: reports research grants from Pfizer and ReumaNederland (Dutch Arthritis Foundation). The remaining authors declare no competing interests. |
| Substance Nomenclature: | 0 (Antirheumatic Agents) 0 (Biological Products) |
| Entry Date(s): | Date Created: 20260309 Date Completed: 20260701 Latest Revision: 20260701 |
| Update Code: | 20260702 |
| DOI: | 10.1016/j.ard.2026.02.005 |
| PMID: | 41796486 |
| Βάση Δεδομένων: | MEDLINE |
καταχωρήστε σχόλιο πρώτοι!